Evidence map›Paper›PMID 30487792›Full record

ArticleFrontiers in immunology2018

Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.

Paulo Rodrigues-Santos, Nelson López-Sejas, Jani Sofia Almeida, Lenka Ruzičková, Patricia Couceiro, Vera Alves, Carmen Campos, Corona Alonso, Raquel Tarazona, Paulo Freitas-Tavares and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Paulo Rodrigues-SantosFaculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.
Nelson López-SejasDepartment of Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba - Reina Sofia University Hospital - University of Córdoba, Córdoba, Spain.
Jani Sofia AlmeidaLaboratory of Immunology and Oncology, Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Lenka RuzičkováHematology Service, Coimbra Hospital and Universitary Centre, Coimbra, Portugal.
Patricia CouceiroLaboratory of Immunology and Oncology, Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Vera AlvesFaculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.
Carmen CamposDepartment of Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba - Reina Sofia University Hospital - University of Córdoba, Córdoba, Spain.
Corona AlonsoDepartment of Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba - Reina Sofia University Hospital - University of Córdoba, Córdoba, Spain.
Raquel TarazonaImmunology Unit, University of Extremadura, Cáceres, Spain.
Paulo Freitas-TavaresHematology Service, Coimbra Hospital and Universitary Centre, Coimbra, Portugal.
Rafael SolanaDepartment of Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba - Reina Sofia University Hospital - University of Córdoba, Córdoba, Spain.
Manuel Santos-RosaFaculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.
University of Coimbra · PTInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversity of Córdoba · ESUniversidad de Extremadura · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are a very important component of the innate immune response involved in the lysis of virus infected and tumor cells. Aging has a profound impact in the frequency, phenotype and function of NK cells. Chronic Myeloid Leukemia (CML) is caused by the BCR-ABL gene formation encoding aberrant oncoprotein tyrosine kinase. Treatment with tyrosine kinase inhibitors (TKIs) induces durable deep molecular response. The response to treatment and life expectancy is lower in older patients with chronic phase of CML than in younger patients. In this work we analyse NK cells from TKI-treated CML patients and healthy controls stratified according to age. We have analyzed the expression of NK receptors, activation markers, NK cell differentiation in CD56

Indexed as

Age FactorsAdultAgedAged, 80 and overAgingAntineoplastic AgentsCell DifferentiationFemaleGenes, ablHumansK562 CellsKiller Cells, NaturalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte ActivationMaleMiddle AgedAntineoplastic AgentsProtein Kinase Inhibitorsactivation markersagingCMLcytokinesdifferentiation markersNK cell subsetsNK receptorstyrosine kinase inhibitors

Identifiers

PMID30487792
PMCPMC6246921
OpenAlexW2901757042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.